Gene-directed enzyme prodrug therapy (GDEPT) is a promising approach to local management of cancer through targeted chemotherapy. Killing localized tumors by GDEPT in a manner that induces strong antitumor cellular immune responses might improve local management and allow benefit in disseminated cancer. Here we evaluated the combination of nitroreductase (NTR)/ CB1954 GDEPT with high-level expression of heat shock protein 70 (HSP70, a stress protein that can shuttle cytosolic peptides into antigen-presenting cells) for induction of antitumor immunity using adenovirus gene delivery in an aggressive and nonimmunogenic BALB/c syngeneic 4T1 breast cancer model. The mechanism of cell death and spectrum of stress proteins induced are likely to be important determinants of the resulting immune responses. We showed that NTR/CB1954 treatment of 4T1 cells gave both apoptotic and nonapoptotic killing. In vivo killing of 4T1 cells expressing NTR gave weak antitumor immunity and very limited induction of stress proteins including HSP70. High-level coexpression of HSP70 during NTR/CB1954-mediated killing of 4T1 cells in vivo gave much greater protection from tumor challenge (67% long-term survivors compared to 17%) and induced 4T1-specific cytotoxic T-cell responses. The enhancement of antitumor responses resulting from HSP70 coexpression was similar to that conferred by coexpression of GM-CSF.
G ene-directed enzyme/prodrug therapy (GDEPT) or ''suicide'' gene therapy using viral vectors is an attractive alternative approach to cancer therapy, with the potential to give therapeutic ratios superior to those with standard chemo-and radiotherapy. 1 In this setting, a viral vector expressing the therapeutic enzyme is delivered to the tumor cells, usually through administration locally at the tumor site. Enzyme expression can be rendered more selective for tumor cells by using tumor-specific promoters 2, 3 or tumor-specific viral cell entry. 4, 5 The nontoxic prodrug is administered systemically (by intravenous injection) or locally (e.g. by intraperitoneal or intratumoral injection to maximize its concentration within the tumor). We are using the Escherichia coli nitroreductase (NTR)/CB1954
(5-(aziridin1-yl)-2,4-dinitrobenzamide) enzyme/prodrug system, which has the advantages of efficient bystander killing of untransduced tumor cells, and killing is independent of the cell cycle enabling the killing of nondividing tumor cells. [6] [7] [8] [9] E. coli NTR preferentially reduces CB to a cytotoxic 4-hydroxylamine (4HX) derivative instead of a noncytotoxic 2-hydroxylamine; the 4HX derivative can crosslink DNA via a nonenzymatic combination with cellular thiols. A bystander effect is important to suicide killing systems as only a small portion of the tumor cells can realistically be infected in the clinical setting. We have previously shown that NTR/CB1954-mediated GDEPT using replicationdeficient adenoviral vectors can achieve tumor regression or even complete tumor ablation in several mouse xenograft models. 3, 10, 11 Furthermore, GDEPT using NTR/CB1954 has reached the status of clinical studies for liver cancer 12 and locally recurrent prostate cancer (James et al, American Society of Clinical Oncology (ASCO) 2004, abstract 4572).
Although the management of localized disease may be achievable using GDEPT, the successful treatment of disseminated cancer remains a major challenge. Ideally, destruction of the local tumor by the enzymatically activated toxic drug will induce a systemic immune response able to destroy both residual local tumor and distant tumor deposits. Previous studies have shown that the most commonly used suicide gene therapy systems such as thymidine kinase (tk)/ganciclovir (GCV) and cytosine deaminase (CD)/5-fluorocytosine (5-FC) are able to induce an immune response in mice, [13] [14] [15] although this response is often weak and may not occur in the context of a clinical tumor treatment. [13] [14] [15] There is much potential for improvement of this immune response by combination gene therapy. Several immunestimulatory factors have been shown to enhance the immunogenicity of tumor cells and allow immune protection of mice against untreated tumor challenge. The factors evaluated include granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin (IL-2), IL-12, interferon (IFN)-a, IFN-g, B7-1/2, major histocompatibility complex (MHC) class-I/II, Flt3 Ligand (Flt3-L), CD40 Ligand (CD40-L), OX40 Ligand, chemokines, and more recently LIGHT. [16] [17] [18] [19] [20] Also, the inhibition of immune suppressive molecules like TGF-b has been evaluated. 21 GM-CSF is one of the most promising factors and its effects are multiple on the immune system. It serves to expand, activate and mature neutrophils, monocytes and dendritic cells (DCs). 22, 23 Indeed, DCs play a major role in the immune activation process as they are the most proficient antigen-presenting cells (APCs). GM-CSF can enhance the coordinated antitumor effects of CD4 þ and CD8 þ T cells, natural killer cells and antibody-mediated responses. 22, 23 Recently, the involvement of heat shock proteins (HSPs) in the transportation of cellular antigenic peptides to APCs like DCs has been described. 24, 25 Generally, HSPs, which are induced by cellular stress, are molecular chaperones that mediate the assembly and folding of other cytosolic proteins, thereby protecting cells from damage. 26 Inflicting stress on tumor cells, as occurs during suicide gene therapy, may cause the upregulation of various stress proteins and HSPs, which will also be released from fragmenting cells. HSPs, which are able to shuttle cytosolic peptides into APCs include cytosol-located factors such as HSP70, HSP90 and HSP110 and endoplasmic reticulum (ER)-located factors like gp96 and calreticulin. 26 Thus, when peptide-loaded HSPs are released from the cells, they bind to APCs mainly through the CD91 receptor (a2-macroglobulin receptor), CD40 and LOX-1. [27] [28] [29] Once taken up by APCs, the peptides are translocated to MHC class-I molecules, which traffic to the cell surface enabling efficient presentation to CD8 þ T cells, a vital step in raising a systemic antitumor response. 30 Binding of released HSPs to other APC receptors (toll-like receptor (TLR4) and CD14) imparts a danger signal to upregulate costimulatory molecules and induce the release of immunostimulatory cytokines. 31, 32 Indeed, patient tumor-derived HSP-peptide complexes as vaccines is an interesting and promising approach, although this approach is patient-specific and therefore labor intensive. The advantage of involving HSPs for anticancer vaccines is that they associate with a wide variety of peptides representing thereby the cellular proteome specific for the tumor cell (proteomic fingerprint). Due to this high variety, the chance for clonal outgrowth and escape of distinct tumor variants should be much lower than when peptide antigens are used as vaccines. A potential disadvantage of HSP-based vaccines is the breaking of tolerance to chaperoned self, antigens in conjugation with the antitumor response, resulting in an autoimmune response. However, this has not been described in the literature.
A correlation between the mechanism of tumor cell death and induction of an immune response has been proposed. [33] [34] [35] Nonapoptotic cell death (necrosis) is associated with greater induction of HSPs compared to apoptotic cell death, and necrotic cell-based immunization elicits a better immune response compared to cells killed by apoptotic pathways. [33] [34] [35] [36] Taken together, the induction of appropriate tumor cell death together with enhanced HSP expression may lead to enhanced immunization.
In the studies reported here, we investigated whether the high-level coexpression of HSP70 in the context of adenoviral GDEPT using the NTR/CB1954 suicide system is able to improve the immunization effect. For this, we used the highly aggressive and nonimmunogenic BALB/c 4T1 breast cancer model. Killing of 4T1 cells by NTR/CB1954 seemed to involve both apoptotic and necrotic patterns, although killing did not induce significantly enhanced levels of HSP70. We present evidence that coexpression of high levels of HSP70 in tumor cells killed in vivo by NTR/CB1954 significantly improves the resulting antitumor immune effects. It is of interest that coexpression of HSP70 enhanced antitumor immunity to an extent similar to that produced by coexpression of GM-CSF. We suggest the use of HSPs in combination with NTR/CB1954 enzyme/prodrug therapy as a promising strategy to increase the likelihood of a systemic antitumor response in cancer patients.
Materials and methods

Tissue culture
The 4T1 mouse breast cancer cell line was obtained from American Type Culture Collection (ATCC) (CRL-2539). EJ-6-2-Bam-6a (EJ6) was obtained from ATCC (CRL-1888) and was generated by transfecting NIH/3T3 with DNA from the human EJ bladder carcinoma. Both cell lines were cultured as recommended by the supplier. PER.C6 (human embryonic retina cells stably transformed with plasmid PIG.E1A.E1B clone 6) cells were obtained from Crucell (Leiden, The Netherlands). The adenoviral vector producer cell lines 293 and 911 were kindly provided by Professor LS Young (Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK) and were maintained (like PER.C6) in DMEM containing 10% FCS, 10 mM MgCl 2 and 100 IU/ml penicillin/100 mg/ml streptomycin). All cell lines were grown at 371C in a humidified 5% CO 2 atmosphere.
Plasmids and adenoviral construction
The plasmid pCR3.1/HSP70 expressing murine HSP70 was kindly provided by Dr Richard Vile (Molecular Medicine, Program, Mayo Clinic, 200 First Street SW, Rochester, MN). The plasmid pRAJ43 BP 4 consists of murine GM-CSF cDNA (base pair (bp) 33-455) with an optimized Kozak sequence and cloned into SmaI site of pUC19 and is described in detail elsewhere. 37 The adenoviral backbone plasmids pPS1128 (E1 deletion: bp 359-3525) and pPS1160 (E3 deletion: bp 28, 592-30, 470) have been described earlier.
11 CET902 is a pUC19 plasmid containing the mouse CMV immediate early (IE) enhancer/promoter (mCMV; 1.4 kb fragment) and the Simian virus 40 (SV40) late poly(A) signal. To construct CET902/HSP70, the murine HSP70 cDNA was cut out from pCR3.1/HSP70 by NheI/BamHI and the blunted fragment was cloned between the mCMV promoter and the SV40 poly(A) in CET902 using a SmaI site. The plasmid pTX0375 has been described in detail earlier and is a pPS1128 version containing the human CMV IE enhancer/promoter (hCMV)-NTR expression cassette.
11 pPS1128/mCMV-HSP70 and pTX0375/ mCMV-HSP70 were constructed by transferring the mCMV-HSP70-SV40 p(A) expression cassette from CET902/HSP70 into SpeI-blunted pPS1128 or into the blunted PacI site of pTX0375, respectively. The mCMV-HSP70-SV40 p(A) expression cassette was prepared by digestion of CET902/HSP70 plasmid with XmnI, AscI and BstZ17I and blunting with T4 DNA polymerase. The final cassette only contains about 500 bp of the mouse CMV promoter providing high activity. pPS1128/ mCMV-GM-CSF was constructed by cloning the complete expression cassette (1.3 kb) into pPS1128, prepared from CET902/GM-CSF using BstZ17I/AscI and blunted with T4 polymerase.
Adenoviral vector construction
The viruses Ad.hCMV-NTR (also named CTL102) and Ad.CMV-LacZ have been described earlier. 11 The recombinant viruses Ad.hCMV-NTR/mCMV-HSP70, Ad.mCMV-HSP70 and Ad.mCMV-GM-CSF were constructed by homologous recombination in PER.C6 cells. PER.C6 cells were cotransfected with an equimolar mixture of pTX0375/mCMV-HSP70, pPS1128/mCMV-HSP70 or pPS1128/mCMV-GM-CSF, (2 mg each), and pPS1160 (6 mg) into 90% confluent PER.C6 cells. Viruses were harvested, expanded to large scale, purified by double CsCl centrifugation, dialyzed and titered for particles/ml and plaque forming units (PFU)/ml as described in detail elsewhere.
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Western blot analysis
Western blot analysis has been described elsewhere. 38 NTR and HSP70 expression was analyzed from infected (multiplicity of infection (MOI) ¼ 20, 100 and 500) CMT93 cells (negative background for HSP70 and NTR) using 12.5% SDS-PAGE loaded with 20 mg whole cell extract. GM-CSF expression was analyzed from infected 4T1 cells (MOI ¼ 200). Primary and secondary antibodies were used as follows: mouse anti-HSP70 diluted 1:1000 (SPA-810; Stressgen Biotechnologies, Victoria, BC, Canada), sheep anti-NTR diluted 1:1000 (Polyclonal Antibodies, Dyfed, UK), goat anti-GM-CSF diluted 1:1000 (sc-1322; SantaCruz, CA), goat antimouse-IgG-HRP diluted 1:10,000 (A-9917; Sigma, Willingham, UK), donkey anti-sheep-IgG-HRP diluted 1:7500 (Sigma) and rabbit anti-goat-IgG-HRP diluted 1:20,000 (A-5420; Sigma). Enhanced chemiluminescence was carried out using ''Super-Signal West Pico substrate'' (Perbio Science UK Ltd, Tattenhall, UK) and was then analyzed on an Alpha Innotech Imager model # 2.3.1 (GRI Ltd, Essex, UK) as recommended by the supplier.
Proteomic analysis
The 4T1 tumor cells were infected with Ad.hCMV-NTR at 200 PFU/cell and expression of NTR was allowed to occur for 48 h. The cells were then subjected to treatment with 10 mM CB1954 for 24 h. Approximately 10 7 cells were harvested by trypsinization, following aspiration of any floating cells, which were all pooled and washed in PBS and the resulting pellet was homogenized in an icecold lysis buffer comprising MOPS buffer together with protease inhibitors as described at www.kinexus.ca. Following protein determination using the BCA Protein Assay Kit (Pierce, Rockford, IL), 350 mg of the total lysate protein preparation at 1 mg/ml in SDS-PAGE sample buffer was subjected to SDS-PAGE within a single lane that spanned the width of a minigel. Subsequently, the resolved proteins were transferred to a nitrocellulose membrane and multiblotted with the Kinetworks KSHP 1.0 Heat Shock/Stress Protein panel of pan-specific antibodies, which detect APG-1, APG-2, COX-2, eIF2alpha, ERp57, ERp72, GROEL, GRP75, GRP78, GRP94, hHR23B, HIP, HO-1, HO-2, HSC70, HSF4, HSP25, HSP40, HSP47, HSP60, HSP70, HSP90al-pha, HSP105, HSPBP1 and STI1/HOP-p60. The resulting bands were detected by ECL and a Bio-Rad FluorS Max Imager (Bio-Rad, Hercules, CA), and were quantified with Quantity One Software (Bio-Rad) to provide a measure of relative protein expression.
4T1 in vitro infections and cell killing analysis
4T1 cells were infected at a cell density of 1 Â 10 7 /ml for 2.5 hours at 371C in a humidified 5% CO 2 incubator with 200 PFU/cell in infection medium (normal medium but containing only 1% FCS). During infections, cells were gently mixed every 30 minutes. Cells were then pelleted (300 g, 5 minutes) and washed and resuspended in PBS. In case of infection with two viruses, each virus was used at 100 PFU/cell. In vitro cell death was analyzed 2 days after infection using the CellTiter 96 s Aqueous One Solution Cell Proliferation Assay MTS substrate (Promega, Madison, WI) and cell viability was calculated by reading the OD at 450 nm after subtraction of the medium background OD 450 .
Analysis of cell death mechanism
Mechanisms of cell death associated with NTR/CB1954 treatment were analyzed in conjunction with the same in vitro treatment conditions as described in Proteomics analysis. Tumor cells were harvested and washed in PBS. For Annexin V analysis, cells were washed in Annexin V buffer as provided in the Annexin V-FITC Apoptosis Detection Kit II (BD-Pharmingen, San Diego, CA), stained with Annexin V-FITC, counterstained with propidium iodide (PI), and then analyzed after 30 minutes using a BD FACScalibur (10 4 cells were acquired). For TUNEL analysis, PBS-washed cells were fixed in 1% paraformaldehyde and then stored in 70% ethanol at À201C following the instructions of the APO-BRDU kit (BD-Pharmingen). Cells were then treated with TdT enzyme to label the DNA break sites with Br-dU, stained with anti-Br-dU-FITC, counterstained with PI and analyzed using a BD FACScalibur (10 4 cells were acquired).
Mice
Female BALB/c mice (H-2 d , 6-8 weeks old) were obtained from Harlan (Oxon, UK) and were maintained in a temperature-controlled, light-cycled room with food and water ad libitum. Mice were allowed to rest for 1 week before any treatment. Care as well as all experimental procedures were conducted in full compliance with the UK Home Office regulations.
4T1 tumor model
The 4T1 cell line is a highly aggressive and metastatic cell line established from a mammary adenocarcinoma, which arose spontaneously in a BALB/cfC3H mouse. 39 The 4T1 cell line, which expresses H-2 d class I but not class II molecules, is a non-immunogenic tumor model, which does not stimulate a syngeneic antitumor response in vitro or in vivo. The minimal 100%-tumor-inducing dose in BALB/c mice was determined to be 5 Â 10 2 cells. When injected subcutaneously (s.c.) into BALB/c mice, 4T1 cells produce aggressive solid tumors that can spontaneously metastasize primarily to the lung while the primary tumor is growing in situ. The EJ-6-2-Bam-6a, 40 a transformed fibrosarcoma cell line, was used as a syngeneic control tumor.
Immunization and tumor challenge protocols
Adenovirus-transduced 4T1 cells were injected s.c. into the right flank of each naı¨ve mouse in a total volume of 100 ml (day 0). Different experimental groups were injected with cells transduced with single or different combinations of adenoviruses as indicated. After allowing for transgene expression to proceed in vivo until day 2, the time at which maximal transgene expression was demonstrated to occur, 500 ml of a 400 mM solution of CB1954 was injected peritoneally. Unless otherwise stated, on day 21 all mice were challenged with a second contra-lateral injection of 5 Â 10 3 parental 4T1 cells. This dose is 10-fold higher than the minimal lethal dose in naı¨ve mice. A naı¨ve group of mice was also injected with these cells at the same time. All groups of mice in any one experiment were challenged on the same day using the same preparation of cells. Animals were examined regularly for the appearance of tumors by palpation; thereafter, tumors were measured in two perpendicular dimensions using a Vernier calliper 2-3 times per week. Tumor size was expressed as the product of the two diameters of individual tumors. Mice were culled for humane reasons when they exhibited signs of distress, the tumors became too necrotic or when tumors exceeded a cross-sectional area of 160 mm 2 .
ELISPOT assay
Interferon-g-ELISPOT assays were generally performed as described elsewhere. 41 In detail, freshly isolated splenocytes from successfully immunized (and protected) mice were cocultured with irradiated (120 Gy) 4T1 cells using a ratio of 10:1 (E:T) for 7 days. For this, triplicates were seeded in 96 wells format using 3 Â 10 5 splenocytes per 96 wells. On day two after seeding, the coculture was fed with rhIL-2 at 10 U/ml and 100 ml fresh medium (BioWhittaker Ltd, Wokingham, UK). After 7 days of coculture, splenocytes were restimulated overnight with nonradiated 4T1 or EJ6 tumor cells (or mock restimulated) again using an E:T ratio of 10. For the ELISPOT, nitrocellulose-backed 96-well plates (MAHA-S45, Millipore, Billerica, MA) were coated overnight with first antibody clone 554431 (BD-Pharmingen) at 5 mg/ml. The next day, 100 ml of the splenocytes/tumor cell reactions containing 2 Â 10 5 splenocytes was added to each ELI-SPOT 96 wells and plates were incubated overnight. Wells were blocked and then incubated with detection antibody (biotinylated rat anti-mouse IgG) clone 554410 (BDPharmingen) used at 2.5 mg/ml. Spots were detected using avidin-peroxidase 1:800 diluted (A-3151, Sigma) and chromogenic peroxidase substrate (Vector AEC kit SK-4200, Vector Labs, Petersborough, UK) and quantified using the Imaging Associates KS300 system (Thame, UK).
Results
Characterization of viruses and optimization of in vitro infection
The therapeutic vectors used in our experiments are schematically outlined in Figure 1a . All the viruses could be grown to normal titer and showed no indication of instability (data not shown). Gene expression of NTR, HSP70 and GM-CSF by adenovirus-transfected CMT93 tumor cells was analyzed in Western blot experiments (Fig  1b) . CMT93 cells are negative for NTR and have no detectable HSP70. NTR and HSP70 protein levels from Ad.hCMV-NTR/mCMV-HSP70 increased with rising MOI. The same was the case for HSP70 expression from Ad.mCMV-HSP70. HSP70 levels from Ad.mCMV-HSP70 were slightly higher than from the doublerecombinant vector at each MOI used. NTR levels from the double-recombinant vector were comparable to the NTR levels from the Ad.hCMV-NTR vector at 500 PFU/ cell. GM-CSF was clearly detectable from 4T1 cells infected with Ad.mCMV-GM-CSF at 200 PFU/cell (Fig 1b, bottom panel) .
To maximize the likelihood of successful in vivo immunization, we optimized killing in vitro showing an MOI of 200 and a CB concentration of 400 mM being optimal (data not shown).
Mechanism of cell death in NTR/CB1954-killed 4T1 cells
To investigate the mechanism of cell death by NTR/ CB1954, we conducted Annexin V surface staining and TUNEL staining (indicators of apoptosis), both with PI counterstaining (an indicator of necrosis). Forward and side scatter analysis (Fig 2a) showed reduction both in size and granularity of treated tumor cells compared to (Fig 2a) . TUNEL analysis (Fig 2b) failed to show any Br-dU staining while PI staining (Fig 2c) of these fixed cells showed increased numbers of treated cells with reduced DNA content (M1 ¼ 31% compared to 12.9% for untreated cells) and also increased numbers of treated cells accumulated in the non-G1 phases compared to untreated cells.
Broad panel proteomic analysis of stress protein expression in NTR/CB1954-treated 4T1 cells
We wanted to know whether the killing of 4T1 cells with NTR/CB1954 was generally able to induce a cellular stress response. Of interest, we were not able to detect gp96 and HSP70 in NTR/CB1954-killed 4T1 cells using Western blot experiments (data not shown). Therefore, we analyzed the induction of stress proteins in treated 4T1 cells versus untreated 4T1 cells using the Western blotbased Kinexus Kinetworkst HSP screen, which results in densitometric analysis of the resultant bands, an example of which is shown in Figure 3a for cell extract generated from untreated 4T1. In Figure 4b , the normalized (corrected for differences in protein concentration) stress protein densitometric levels are shown. For the treated 4T1 cells, the average of two samples is shown. For 68% of the stress factors, expression was not detectable (28%) or was reduced in the treated compared to the untreated samples (40%). For stress factors where increased expression was observed (32%), the increase was only modest (e.g. ERp72: 1.4-fold; GRP94: 1.9-fold; and GROEL: 1.2-fold) and/or the absolute level was relatively low (e.g. HSP25, HSP60, HSP70 and HO-1). Indeed, the HSP70 band for the treated cell samples was just detectable (see Fig 4a, lane 15 , top band) and slightly increased above the untreated sample. The low level of HSP70 protein expression by the NTR/CB1954-treated 4T1 cells provided the opportunity to evaluate therapy with high-level HSP70 protein combined with NTR in our in vivo model by using a double-recombinant adenoviral vector.
NTR/CB1954-mediated killing of 4T1 can induce protection against 4T1 challenge
To test the possibility that NTR/CB1954 tumor cell killing in situ may contribute to the generation of a specific antitumor immune response, immunization experiments were conducted. To establish the optimum killing conditions, mice were administered a range of doses of cell inocula (5 Â 10 2 to 5 Â 10 6 NTR-expressing 4T1 cells) and were subsequently treated in vivo with escalating CB1954 doses. The optimum conditions involved inocula of 5 Â 10 3 or 5 Â 10 4 cells and a single peritoneal 500 ml injection of 400 mM CB1954 (data not shown). Mice that rejected the initial inoculation of tumor cells from two groups administered with either 5 Â 10 3 or 5 Â 10 4 NTR-expressing 4T1 cells, respectively, were challenged with 5 Â 10 3 unmodified 4T1 cells (Fig 4a) on the opposite flank at 21 days (white bars) or 80 days (black bars) following cell inoculation, the latter to assess the induction of a long-term antitumoral immune response. All naı¨ve mice developed progressively growing tumors by day 10 and reached compulsory killing by day 25 postchallenge. Rejection of the challenge cells showed a dose-dependent response with respect to the numbers of NTR/CB1954-killed cells used for vaccination, irrespective of the time of challenge (Fig 4a) . Immunization with the lower dose of 5 Â 10 3 killed cells conferred very limited protection from challenge compared to naı¨ve mice, while To assess the specificity of the protection observed upon vaccination with NTR/CB1954 killed cells, mice vaccinated with either 5 Â 10 3 or 5 Â 10 4 NTR-expressing 4T1 cells were challenged after 80 days with another syngeneic tumor, EJ6, a mouse fibrosarcoma. Immunization with 4T1 cells failed to protect any mice from challenge with EJ6 cells (Fig 4b) , although two mice showed slightly delayed growth but finally also grew out (data not shown).
Enhancement of antitumor immunity by coexpression of murine HSP70
To determine whether the effects of NTR/CB1954 killing in the immunization model could be improved by expression of the costimulatory molecule HSP70, mice received a single immunization consisting of 4T1 cells transduced with either the single-recombinant virus carrying the NTR gene or the double-recombinant virus carrying both NTR and HSP70 genes. After 2 days, animals were injected peritoneally with CB1954 and subsequently challenged with 5 Â 10 3 unmodified 4T1 cells on the opposite flank. Two different vaccination doses were used, a low dose of 5 Â 10 4 and a high dose of 5 Â 10
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. All animals, including naı¨ve mice, were challenged with 5 Â 10 3 unmodified 4T1 cells at 21 days postcell inoculation and followed for tumor appearance, tumor growth and overall survival. The results indicate that coexpression of HSP70 at the time of tumor cell killing by NTR/CB1954 led to a stronger antitumor immune response (Fig 5a and b) . For both groups, NTR and NTR/HSP70, a higher dose of immunizing cells was more effective in protecting mice against subsequent challenge with 4T1 cells. The difference between the NTR high-dose and the NTR þ HSP70 high-dose groups was significant by the last time point shown (day 31; Po.05) but not between the respective low-dose groups (P ¼ .21), supporting our theory that the antitumor immune response is dependent on the dose of immunizing inoculum. Of interest, only the average tumor size of the NTR þ HSP70 high-dose group was static by day 31, while the average tumor sizes of all other groups were still progressing, suggesting an enhanced immune response by HSP70 coexpression.
High-level HSP70 during NTR/CB1954-induced cell death increases long-term animal survival and elicits 4T1-specific IFN-g-secreting lymphocytes
An independent experiment was conducted to establish reproducibility of the HSP70 enhancement effect and to evaluate long-term immune protection using a high immunization dose of 5 Â 10 5 4T1 cells. Animals immunized with NTR-HSP70-expressing cells showed consistently a high long-term survival rate regarded as disease-free (67% ; Fig 6a) . By contrast, animals receiving NTR-expressing cells showed only a modest long-term survival advantage with only one mouse surviving tumorfree for more than 3 months (17%). Of interest, immunization with cells expressing HSP70 alone and subsequent treatment with CB1954 did not protect any mice against the emergence of tumors at the inoculation site, where progressively growing tumors developed, which took approximately 30 days to reach the size of compulsory killing. For the reason mentioned, the survival of challenge for the HSP70 only group is irrelevant and is not shown in Figure 6a .
To confirm that immune effector cells are very likely to be important for the antitumor response shown in Figure 6a , we analyzed the potency with which splenocytes from successfully immunized and protected animals were reactivated by exposure to tumor cells 3 months after vaccination, using an IFN-g ELISPOT assay. As shown in Figure 6b , splenocytes restimulated with 4T1 cells but not EJ6 cells were efficiently activated.
Enhancement of antitumor immunity as a result of coexpression of HSP70 is similar to that due to coexpression of GM-CSF GM-CSF is one of the most commonly used and most promising immune stimulatory factors for cancer immunotherapy. 22, 23 It is thought to stimulate the recruitment, proliferation and maturation of DCs thereby enhancing antigen presentation to MHC class-I-and -IIrestricted T cells. 22, 23 To compare the stimulatory effects of HSP70 and GM-CSF on antitumor immunity and survival in our animal model, 4T1 cells were transduced with the following vector combinations, each vector at 100 PFU/cell: group NTR, Ad.hCMV-NTR plus Ad.CMV-LacZ; group GM-CSF, Ad.mCMV-GM-CSF plus Ad.CMV-LacZ; group NTR þ GM-CSF, Ad.hCMV-NTR plus Ad.mCMV-GM-CSF; and group NTR þ HSP70, Ad.hCMV-NTR plus Ad.mCMV-HSP70. Each animal was injected with 5 Â 10 5 infected cells and treated in vivo with CB1954 peritoneally. Consistent with previous experiments, vaccination with 4T1 cells transduced with the NTR virus induced only relatively weak protection. In contrast, vaccination with 4T1 cells expressing GM-CSF alone (no NTR/CB1954 killing) had a significant effect on rejection of challenge and was even superior to vaccination with the NTR/ CB1954-killed cells. Vaccination with such cells led to the growth of tumors at the inoculation site to palpable size, after which the tumors became static or slowly regressed (data not shown), an effect not observed following vaccination with cells expressing HSP70 alone. The presence of GM-CSF in the tumor environment at the time of NTR/CB1954 killing elicited increased protection against tumor challenge, with 57% (4/7) of mice rejecting the challenge 30 days after challenge (Fig 7a) . The combination of NTR þ GM-CSF or NTR þ HSP70 resulted in identical results for both long-term survival (57%, 4/7) and average tumor size at the latest time point (7.0 mm 2 ). Figure 7b shows the average tumor size over time and confirms the results shown in Figure 6a . The size of challenge tumors in the NTR þ GM-CSF group was very similar at all time points to that in the NTR þ HSP70 group. By day 24, the average tumor size of the NTR group was significantly different from the average tumor size of the NTR þ HSP70 group (Po.03). Also, the average tumor sizes for both combination groups (NTR þ HSP70 and NTR þ GM-CSF) were declining by day 24 compared to the single-treatment groups NTR and GM-CSF, supporting the idea that both HSP70 and GM-CSF enhance the immune response in the context of GDEPT-mediated tumor therapy.
Discussion
The NTR/CB1954 enzyme/prodrug combination is an attractive suicide killing system as it creates a potent alkylating, genotoxic drug able to kill cells regardless of their replication status. Its bystander effect is mediated by diffusion of toxic drug and/or drug metabolites and killing is independent of functional p53, enabling in theory the treatment of all tumor types. [6] [7] [8] [9] The application of this system has reached the stage of clinical evaluation for liver cancers and locally recurrent prostate cancer (James et al, ASCO, abstract 4572) using the Ad5 vector CTL102. The first stage of clinical evaluation involved injecting escalating single doses of CTL102 into the liver tumors of operable patients in order to quantify NTR expression in the tumor following surgical resection. NTR expression was quantified by immunohistochemical analysis on sections taken throughout the excised tumors. Single CTL102 doses of 5 Â 10 11 particles resulted in NTR expression in about two-thirds of all sections through the tumor and in an estimated 3-5% of all cells in the tumors. Even with a strong bystander effect, it is unlikely that direct killing alone will completely eradicate the injected tumors. However, local killing that induces a systemic antitumor immune response could destroy residual local tumor as well as metastatic tumor deposits.
In this context, the induction of an immune bystander effect has been reported for the HSV tk/GCV and CD/5-FC suicide systems. [13] [14] [15] Combination with immune stimulatory genes to enhance this immune bystander effect has been extensively studied, including combination with GM-CSF, IL-2, IL-4, IL-6, IL-12, IL-18, IFN-a, B7-1 and MCP-1. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Overall, results have been variable and have not led to reliable improvements in the immunotherapy of cancer, but they have indicated that GM-CSF is one of the most promising immune enhancers. To our knowledge, only one study combining NTR/CB1954 with GM-CSF has been reported, using the AB22 mesothelioma and MC26 colorectal murine cancer models. 37 These studies suggested that NTR/CB1954 cell killing can have an immune bystander effect and in both models the enhancement achieved by coexpression of GM-CSF was modest, regarding both the reduction in mean tumor volume and increase in animal survival, and no cures were observed.
In this report, we describe an approach to improving the immune bystander effect of NTR/CB1954 adenoviral GDEPT by coexpression of murine HSP70. The approach was evaluated using the 4T1 breast cancer model. This model cell line is highly metastatic, nonimmunogenic and expresses surface MHC class-I molecules, 52 which makes it appropriate for immunotherapy evaluation. Additionally, it resembles clinically relevant tumors in that it produces relevant amounts of the immune suppressor TGF-b to suppress the host's potential immune attack. 53 Previous studies on HSP gene therapy have been reported that use plasmid-derived mycobacterial HSP65, 54 ratderived HSP70 55 or a secretable form of murine HSP70 intended to increase the level of extracellular HSP70/ peptide complexes available to APCs. 56 However, to our knowledge, no studies on the combination of GDEPT with HSP gene therapy have been reported.
The mechanism of GDEPT-induced tumor cell death may determine whether an antitumor immune response is induced and/or its potency. It has been shown that nonapoptotic (necrotic) cell death of tumor cells induces higher levels of HSP70 and is associated with increased immunogenicity, release of inflammatory cell contents, increased secretion of proinflammatory Th1-type cytokines and macrophage activation. 35 Melcher et al 34 showed that coexpression of Bcl-2 in CMT93 cells stably expressing HSV tk reversed the apoptotic cell killing usually observed upon GCV application, giving more necrotic and more highly immunogenic cell killing, and that this reversion was associated with the induction of HSP70 expression. Also shown here, stable expression of HSP70 inhibited the ability of CMT93 cells to form tumors in mice. Our mechanistic studies suggest that both apoptotic and nonapoptotic cell death occur in 4T1 after NTR/ CB1954 killing. Double-positive cells are likely to represent late apoptotic cells that are no longer able to exclude PI. Palmer et al 57 suggested that mainly apoptotic cell death occurred in SKOV3 cells killed by NTR/ CB1954 and that this was dependent on caspase 8 and 9. Cell death after CB1954 application in NTR-recombinant transgenic mice was also reported to be apoptotic. 9 We generated four recombinant adenoviral vectors to evaluate whether high-level HSP70 coexpression with NTR increases the immunogenicity of 4T1 cells and to compare this effect with that of coexpressing GM-CSF. The 4T1 cells were readily infectable by Ad5 vectors, reaching close to 100% transduction using 200 PFU/cell (data not shown) without major toxicity. At this MOI, low concentrations of CB1954 (10 mM) resulted in very efficient cell killing in vitro.
Of interest, we were not able to induce expression of endogenous HSP70 or gp96 in 4T1 cells in vitro either by NTR/CB1954 killing or by heat shock (data not shown). We also analyzed the induction of a broad panel of cellular stress proteins using the sensitive Kinexus Kinetworks TM screen. Overall, inductions were very modest and the only really high induction rate was achieved for HSP25 (59-fold) although the absolute level was still low. HSP70 was induced 2.5-fold, but again the absolute level after induction was very low. From these data, we concluded that high levels of coexpressed HSP70 could provide a means of enhancing the immune response obtained by killing tumor cells in vivo with NTR/CB1954.
In our in vivo experiments, we were able to show that vaccination with NTR/CB1954-killed 4T1 cells can, to a certain extent, protect animals efficiently from challenge with 4T1 but not from challenge with the unrelated syngeneic EJ6 fibrosarcoma. This protection was clearly dependent on the vaccination cell dose and was even more evident when challenge was delayed from 21 to 80 days after immunization. Vaccination with cells coexpressing both NTR and HSP70 clearly gave better protection, in a manner that was reproducible (three independent experiments) and, again, cell dose dependent. This dose dependence indicates that a certain threshold of tumor antigens presented to APCs is crucial in inducing effective antitumor immunity in the 4T1 model. In the long-term survival experiment described (in Fig 6a) , the NTR/ HSP70 cell vaccine was able to protect 67% (4/6) of the animals against a dose of tumor challenge cells that was 10-fold higher than that giving 100% tumor take. NTR treatment alone protected 17% of the animals (2/6). These results were confirmed in two further independent experiments (data not shown). Splenocytes from successfully immunized animals showed a strong IFN-g response specific for restimulation with 4T1 cells but not EJ6 cells, thus showing a specific Th1-type induction despite BALB/c mice having a Th2 bias. 58 Vaccination with cells transduced by the NTR/HSP70 virus gave antitumor effects very similar to those observed following vaccination with cells transduced by the NTR/GM-CSF virus. Given that GM-CSF is the immune stimulatory protein reported to give the most consistent and potent antitumor immunity, these results suggest that combining expression of HSPs with GDEPT has much potential. Also, including both HSP70 and GM-CSF could further enhance the antitumor immune response of GDEPT by additive or synergistic actions.
In conclusion, we suggest that combining NTR/ CB1954-mediated GDEPT with high-level expression of HSP70 (or other relevant HSPs) is a promising approach to improve tumor immunotherapy. Whether these approaches show additive or synergistic effects when combined with radiotherapy or chemotherapy remains to be determined.
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